Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).
about
The role of pattern-recognition receptors in graft-versus-host disease and graft-versus-leukemia after allogeneic stem cell transplantationClinical applications of palifermin: amelioration of oral mucositis and other potential indicationsIncomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutionsEfficacy of palifermin in the hematopoietic stem cell transplant settingSeparating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants.Optimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms.Allogeneic hematopoietic cell transplantation: the state of the artThe Wnt agonist R-spondin1 regulates systemic graft-versus-host disease by protecting intestinal stem cells.The pathophysiology of chronic graft-versus-host disease: the unveiling of an enigmaKeratinocyte growth factor (KGF) enhances postnatal T-cell development via enhancements in proliferation and function of thymic epithelial cellsPathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation.Peritransplant palifermin use and lymphocyte recovery after T-cell replete, matched related allogeneic hematopoietic cell transplantation.The gastrointestinal tract: properties and role in allogeneic hematopoietic stem cell transplantation.CD34+ selection and the severity of oropharyngeal mucositis in total body irradiation-based allogeneic stem cell transplantationPhase I study of the tolerability and pharmacokinetics of palifermin in children undergoing allogeneic hematopoietic stem cell transplantation.Prevention and treatment of oral mucositis in children with cancer.Increasing and worsening late effects in childhood cancer survivors during follow-up.Oral graft-versus-host disease.Immune reconstitution and implications for immunotherapy following haematopoietic stem cell transplantationLong-term follow-up of a phase I/II randomized, placebo-controlled trial of palifermin to prevent graft-versus-host disease (GVHD) after related donor allogeneic hematopoietic cell transplantation (HCT).The Impact of Palifermin Use on Hematopoietic Cell Transplant Outcomes in ChildrenAcute graft-versus-host disease: from the bench to the bedside.Keratinocyte growth factor.Emerging drugs for acute graft-versus-host disease.Prevention and treatment of oral mucositis in patients receiving chemotherapyClinical effectiveness of palifermin in prevention and treatment of oral mucositis in children with acute lymphoblastic leukaemia: a case-control studyGuideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation.Pharmacokinetic evaluation of palifermin for mucosal protection from chemotherapy and radiation.Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients.Improving engraftment and immune reconstitution in umbilical cord blood transplantation.Palifermin for prevention of oral mucositis in allogeneic hematopoietic stem cell transplantation: a single-institution retrospective evaluation.Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease.Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients.In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden.The role of bacteria and pattern recognition receptors in GVHDIs It Time to Reconsider the Lipopolysaccharide Paradigm in Acute Graft-Versus-Host Disease?Gut protection by palifermin during autologous haematopoietic SCT.Impact of palifermin on incidence of oral mucositis and healthcare utilization in children undergoing autologous hematopoietic stem cell transplantation for malignant diseases.Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors.
P2860
Q26824436-97A7D34B-3911-4637-97BA-32E6BB66C61FQ26852139-442BDA49-5F96-4D6C-8A75-40D03D7ADC7AQ27021524-779CD1A3-010F-4FB3-BFAC-71B09DA410C6Q27021790-D0909198-BB4E-484A-BEA1-EC676F7C0610Q33685495-6C814365-C249-4AA2-A826-B689CA87BCACQ33745865-5F61CE7E-2659-40A2-B199-C41E8FB10BCCQ33771667-0C0DFE23-F2E0-4A1E-BE96-781C828249E6Q34145155-D49DC847-63ED-4885-BEAF-6B6CFD509FE5Q34577694-CC43A3C2-5F58-40BD-99BC-ABFA988F5F78Q35084404-0330B00A-FCC4-4DDD-A842-BF5FAC229E4FQ35804466-B08BEF1A-C14D-4D80-84F9-F8591C6E4BEEQ36130498-C320D9C0-57FC-4860-AD39-EE214BB695C9Q36247091-708C6D71-C8ED-4890-A81B-7463B945C17FQ36264109-43FCB856-662A-4977-AFB8-FC12DF7BF050Q36403184-829F1708-44D4-4CA9-BB07-A8868A0FF6FAQ36515670-DD662ED1-200E-44B7-8FC1-07FFBBD46E5AQ36596933-EFF0770D-F490-4CC4-ACBB-9F8752CE037BQ36841132-4B4560D4-29F4-4B37-9187-D906419180CCQ36932886-442B943E-28C4-4B5B-8F29-B24E3766289AQ36959201-2B5EE17E-F1E1-40A8-8FFA-3916E2A42970Q37013066-876DE1F9-CC61-4643-81BA-91979848FD9FQ37104266-3AC7C6EA-966A-4967-BF72-4A56B1246FC5Q37420496-CD67B856-C621-4CEF-B774-C706831126C6Q37489900-732E0898-232F-40DB-953B-09D9B2D31843Q37515433-A1A18CA5-5BFB-4EEE-AEEE-AD892DE9A404Q37605224-24576223-E3E0-4279-BDE1-18AAE29BB708Q37667340-A9322118-F8E5-4B89-B3CD-5DFB450E0BFDQ37683584-AB248F90-D0E6-4EFD-88FF-AA0707BF25C6Q37854688-39055B63-3F6E-4CB7-8D84-8A0D833AF7D3Q38044278-F554239A-0E36-4F9D-B47E-A6775391F3CAQ38194133-57DC046E-54C0-4992-A875-CC1A38839578Q38384344-7BB87817-E951-45E1-B768-BB46F06343EEQ38460376-6A9C5FFD-8875-47EF-AF63-C8A57250FB81Q39847507-76FF943B-A409-4835-89DA-CC64757D7DD3Q40264385-0840A1B4-9003-452F-9B3B-15A2ABFBCB96Q41218452-67284C11-4AAF-41DD-AE03-2CD0CFCCEDD4Q41355730-6FA8510E-AE36-4C03-B512-5A995734E208Q45047418-E0207302-19B7-44A6-B6B9-DDE5AE665452Q45302802-4E9CB65B-A881-4F8C-B07A-38227AE58C93Q47404146-48E71068-D113-47F5-8084-5EA29D041AF3
P2860
Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Phase 1/2 randomized, placebo- ...... m cell transplantation (HSCT).
@ast
Phase 1/2 randomized, placebo- ...... m cell transplantation (HSCT).
@en
type
label
Phase 1/2 randomized, placebo- ...... m cell transplantation (HSCT).
@ast
Phase 1/2 randomized, placebo- ...... m cell transplantation (HSCT).
@en
prefLabel
Phase 1/2 randomized, placebo- ...... m cell transplantation (HSCT).
@ast
Phase 1/2 randomized, placebo- ...... m cell transplantation (HSCT).
@en
P2093
P2860
P921
P1433
P1476
Phase 1/2 randomized, placebo- ...... m cell transplantation (HSCT).
@en
P2093
Anne Goldman
Daniel J Weisdorf
James L M Ferrara
Samuel Silver
Thomas Braun
Todd Defor
P2860
P304
P356
10.1182/BLOOD-2006-04-017780
P407
P577
2006-07-11T00:00:00Z